BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12820314)

  • 21. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
    Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of serum tumor markers in the diagnosis of gastric cancer.
    Fan B; Xiong B
    Hepatogastroenterology; 2011; 58(105):239-45. PubMed ID: 21510322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
    Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
    Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour markers in gastric cancer.
    Roberts PJ; Haglund C; Onali M; Kuusela P
    Ann Chir Gynaecol; 1989; 78(1):38-40. PubMed ID: 2667447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of tumor markers in diagnosing metastases of gastric cancer: preoperative diagnostics (part I)].
    Kurygin AA; Maĭstrenko NA; Khrykov GN; Beliak NP
    Vestn Khir Im I I Grek; 2009; 168(4):16-9. PubMed ID: 19947409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEA and CA 19.9 in gastric juice and serum: an aid in the diagnosis of gastric carcinoma?
    Harrison JD; Stanley J; Morris DL
    Eur J Surg Oncol; 1989 Jun; 15(3):253-7. PubMed ID: 2737312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
    Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
    Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Determination of the tumor marker CA 72-4 in gastric carcinoma].
    Martín-Pérez E; Fernández-Arjona M; Baza B; Villanueva C; Larrañaga E; Serrano PA; Clerigué A
    Rev Esp Enferm Dig; 1993 Feb; 83(2):92-6. PubMed ID: 8471361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Usefulness of biochemical tumor markers (CEA, Ca 19-9, ferritin and sialic acid) in diagnosis and prognosis of colonic neoplasms].
    Krasnodebski IW
    Wiad Lek; 1998; 51(3-4):132-41. PubMed ID: 9658987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical courses of serum tumor markers--4 case reports.
    Klapdor R; Bahlo M; Babinski A
    Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Assay of serum carbohydrate antigen (CA) 19-9 in the diagnosis of gastric cancer].
    Nishida K; Yamamoto T; Yoshioka K; Iida M; Miyagawa H; Yoshikawa T; Sugino S; Kondo M
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):101-8. PubMed ID: 3455804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
    Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
    Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
    Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.
    Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH
    J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.